Synthesis and evaluation of novel bifunctional chelating agents based on 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid for radiolabeling proteins.

[1]  P. Fraker,et al.  Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril. 1978. , 2012, Biochemical and biophysical research communications.

[2]  B D Kahan,et al.  Human colonic adenocarcinoma cells , 1976, In Vitro.

[3]  M. Brechbiel,et al.  A new and convenient method for purification of 86Y using a Sr(II) selective resin and comparison of biodistribution of 86Y and 111In labeled Herceptin. , 2002, Nuclear medicine and biology.

[4]  L. Chappell,et al.  In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications. , 2002, Nuclear medicine and biology.

[5]  M. Brechbiel,et al.  Novel chelating agents for potential clinical applications of copper. , 2002, Nuclear medicine and biology.

[6]  R. Joyce,et al.  Zevalin: 90yttrium labeled anti-CD20 (ibritumomab tiuxetan), a new treatment for non-Hodgkin's lymphoma. , 2001, Current pharmaceutical biotechnology.

[7]  W. Goddard,et al.  Chelators for radioimmunotherapy: I. NMR and ab initio calculation studies on 1,4,7,10-tetra(carboxyethyl)-1,4,7,10-tetraazacyclododecane (DO4Pr) and 1,4,7-tris(carboxymethyl)-10-(carboxyethyl)-1,4,7,10-tetraazacyclododecane (DO3A1Pr). , 2001, Inorganic chemistry.

[8]  J. Shively,et al.  An improved method for conjugating monoclonal antibodies with N-hydroxysulfosuccinimidyl DOTA. , 2001, Bioconjugate chemistry.

[9]  L. Chappell,et al.  Synthesis, conjugation, and radiolabeling of a novel bifunctional chelating agent for (225)Ac radioimmunotherapy applications. , 2000, Bioconjugate chemistry.

[10]  M. Mayo,et al.  Improved synthesis of the bifunctional chelating agent 1,4,7,10-tetraaza-N-(1-carboxy-3-(4-nitrophenyl)propyl)-N',N'',N'''-tri s(acetic acid)cyclododecane (PA-DOTA). , 1999, Bioorganic & medicinal chemistry.

[11]  L. Chappell,et al.  Spectrophotometric method for determination of bifunctional macrocyclic ligands in macrocyclic ligand-protein conjugates. , 1999, Nuclear medicine and biology.

[12]  C. Meares,et al.  Total solid-phase synthesis of 1,4,7,10-tetraazacyclododecane-N,N', N'',N'''-tetraacetic acid-functionalized peptides for radioimmunotherapy. , 1999, Bioconjugate chemistry.

[13]  M. Port,et al.  Structure and dynamics of all of the stereoisomers of europium complexes of tetra(carboxyethyl) derivatives of dota: ring inversion is decoupled from cooperative arm rotation in the RRRR and RRRS isomers , 1998 .

[14]  I. Pastan,et al.  Stereochemical influence on the stability of radio-metal complexes in vivo. Synthesis and evaluation of the four stereoisomers of 2-(p-nitrobenzyl)-trans-CyDTPA. , 1997, Bioorganic & medicinal chemistry.

[15]  M. Brechbiel,et al.  Purification of p-nitrobenzyl C-functionalized diethylenetriamine pentaacetic acids for clinical applications using anion-exchange chromatography. , 1997, Journal of chromatography. A.

[16]  S. Srivastava.  Criteria for the selection of radionuclides for targeting nuclear antigens for cancer radioimmunotherapy. , 1996, Cancer biotherapy & radiopharmaceuticals.

[17]  T. Wheldon,et al.  Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  Qian Zhao,et al.  Analyzing Lanthanide-Induced Shifts in the NMR Spectra of Lanthanide(III) Complexes Derived from 1,4,7,10-Tetrakis(N,N-diethylacetamido)-1,4,7,10-tetraazacyclododecane , 1995 .

[19]  J. Shively,et al.  A facile, water-soluble method for modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates. , 1994, Bioconjugate chemistry.

[20]  T. Koike,et al.  Novel pendant-type macrocyclic bifunctional chelating agents: (carboxymethyl)amino derivatives of 2-(4-nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid and their complex formation with yttrium(III) , 1993 .

[21]  M. Brechbiel,et al.  Convenient synthesis of bifunctional tetraaza macrocycles. , 1992, Bioconjugate chemistry.

[22]  M. Brechbiel,et al.  Backbone-substituted DTPA ligands for 90Y radioimmunotherapy. , 1991, Bioconjugate chemistry.

[23]  S. Mirzadeh,et al.  Improved in vivo stability and tumor targeting of bismuth-labeled antibody. , 1990, Cancer research.

[24]  R. Jensen,et al.  Characteristics of cell lines established from human gastric carcinoma. , 1990, Cancer research.

[25]  D. Parker.  Tumour targeting with radiolabelled macrocycle–antibody conjugates , 1990 .

[26]  S. Mirzadeh,et al.  Radiometal labeling of immunoproteins: covalent linkage of 2-(4-isothiocyanatobenzyl)diethylenetriaminepentaacetic acid ligands to immunoglobulin. , 1990, Bioconjugate chemistry.

[27]  S. Denardo,et al.  The peptide way to macrocyclic bifunctional chelating agents: synthesis of 2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,N',N",N'''-tetraacetic acid and study of its yttrium(III) complex. , 1988, Journal of the American Chemical Society.

[28]  D. E. Simpson,et al.  Synthesis of 1-(p-isothiocyanatobenzyl) derivatives of DTPA and EDTA. Antibody labeling and tumor-imaging studies , 1986 .

[29]  S. Larson,et al.  Prolonged binding of a radiolabeled monoclonal antibody (B72.3) used for the in situ radioimmunodetection of human colon carcinoma xenografts. , 1984, Cancer research.

[30]  P. Durbin.  Metabolic characteristics within a chemical family. , 1959, Health physics.

[31]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.